Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Capstone Therapeutics Corp. (CAPS) had Normalized Income after Taxes of $-16.78M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$12.48M |
|
$-16.79M |
|
$9.39M |
|
$3.08M |
|
$21.01M |
|
$-8.53M |
|
$-1.08M |
|
$-9.61M |
|
$-9.60M |
|
$-16.79M |
|
$-16.79M |
|
$-16.79M |
|
|
Normalized Income after Taxes |
$-16.78M |
$-8.53M |
|
$-6.57M |
|
5.32M |
|
5.32M |
|
$-3.17 |
|
$-3.17 |
|
| Balance Sheet Financials | |
$23.00M |
|
$2.08M |
|
$28.38M |
|
$51.38M |
|
$22.92M |
|
$9.34M |
|
$16.00M |
|
$38.92M |
|
$12.42M |
|
$-7.85M |
|
$12.45M |
|
8.77M |
|
| Cash Flow Statement Financials | |
$-4.41M |
|
$-6.91M |
|
$12.12M |
|
$0.01M |
|
$0.73M |
|
$0.72M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.00 |
|
-- |
|
-- |
|
0.43 |
|
1.88 |
|
24.70% |
|
-68.37% |
|
-68.37% |
|
-- |
|
-77.04% |
|
-134.56% |
|
$-4.53M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
0.55 |
|
2.56 |
|
35.09 |
|
-135.14% |
|
213.91% |
|
-32.68% |
|
-77.02% |
|
$1.42 |
|
$-0.85 |
|
$-0.83 |
|